Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.

Key Points

• To analyze the clinical outcomes of venetoclax combined with azacitidine against the 7+3 induction treatment in acute myeloid leukemia.
• Conducted a real-world analysis comparing treatment outcomes of two groups
• Evaluated clinical outcomes based on treatment response and survival rates
• Included diverse patient population receiving either regimen
• Found differences in treatment effectiveness between the two regimens
• Identified implications for patient management based on therapeutic responses